In 2004, Kim et al. first introduced molecular markers into prognostic model of ccRCC [10], which based on a combination of clinical and molecular predictors included metastasis status, T stage, Eastern Cooperative Oncology Group performance status, as well as immunohistochemically staining of p53, CA9, and vimentin. Here, TP53 is linked to nonpapillary renal cell carcinoma.